

IN THE SPECIFICATION:

Amend the paragraph beginning at Page 59, line 29 as follows:

Where conditions of inflammation are present in the patient being treated, an auxiliary therapeutic agent is optionally coadministered which comprises one or more members independently selected from the group consisting essentially of (1) anti-inflammatory corticosteroids for oral, injectable, topical, ophthalmic, inhalation, or nasal administration useful in treating inflammatory conditions, preferably independently selected from alclometasone dipropionate; amcinonide; beclomethasone dipropionate; betamethasone; betamethasone benzoate; betamethasone dipropionate; betamethasone sodium phosphate; betamethasone sodium phosphate and acetate; betamethasone valerate; clobetasol propionate; clocortolone pivalate; cortisol; cortisol acetate; cortisol butyrate; cortisol cypionate; cortisol sodium phosphate; cortisol sodium succinate; cortisol valerate; cortisone acetate; desonide; desoximetasone; dexamethasone; dexamethasone acetate; dexamethasone sodium phosphate; diflorasone diacetate; fludrocortisone acetate; flunisolide; fluocinolone acetonide; fluocinonide; fluorometholone; flurandrenolide; halcinonide; medrysone; methylprednisolone; methylprednisolone acetate; methylprednisolone sodium succinate; mometasone furoate; paramethasone acetate; prednisolone; prednisolone acetate; prednisolone sodium phosphate; prednisolone tebutate; prednisone; triamcinolone; triamcinolone acetonide; triamcinolone diacetate; and triamcinolone hexacetonide; (2) non-steroidal analgesic, antipyretic and anti-inflammatory active agents preferably independently selected from (i) salicylic acid derivatives preferably consisting essentially of aspirin; sodium salicylate; methyl salicylate; choline magnesium trisalicylate; salsalate; diflunisal; salicylsalicylic acid; sulfasalazine; olsalazine; (ii) para-aminophenol derivatives preferably consisting essentially of

acetaminophen; (iii) indole and indene acetic acids preferably consisting essentially of indomethacin; sulindac; and etodolac; (iv) heteroaryl acetic acids preferably consisting essentially of tolmetin; diclofenac; and ketorolac; (v) arylpropionic acids preferably consisting essentially of ibuprofen; naproxen; flurbiprofen; ketoprofen; fenoprofen; and oxaprozin; (vi) anthranilic acids preferably consisting essentially of mefenamic acid; meclofenamic acid; flufenamic acid; tolfenamic acid; and etofenamic acid; (vii) enolic acids preferably consisting essentially of meloxicam; piroxicam; and tenoxicam; (viii) pyrazolon derivatives preferably consisting essentially of phenylbutazone; and oxyphenthatrazone; (ix) alkanones preferably consisting essentially of nabumetone; (x) apazone; (xi) tenidap; and (xii) nimesulide; (3) potent opioid agonist analgesics preferably independently selected from alfentanil hydrochloride; anileridine; anileridine hydrochloride; brifentanil hydrochloride; carfentanil citrate; codeine; codeine phosphate; codeine sulfate; fentanyl citrate; hydromorphone hydrochloride; levomethadyl acetate; levomethadyl acetate hydrochloride; levorphanol tartrate; lofentanil oxalate; meperidine hydrochloride; methadone hydrochloride; methadyl acetate; morphine sulfate; ocfentanil hydrochloride; oxycodone; oxycodone hydrochloride; oxycodone terephthalate; oxymorphone hydrochloride; pentamorphone; and sufentanil citrate; (4) proteinaceous endogenous and synthetic opioid analgesics comprising enkephalins, endorphins, and dynorphins, which are selective and nonselective agonists and antagonists of the μ , κ , and δ opioid receptor subtypes, preferably independently selected from [Leu⁵] and [Met⁵]enkephalin; dynorphin A and B; α - and β -neoendorphin; [D-Ala²,MePhe⁴,Gly(ol)⁵]enkephalin (DAMGO); [D-Pen²,D-Pen⁵]enkephalin (DPDPE); [D-Ser²,Leu⁵]enkephalin-Thr⁶ (DSLET); [D-Ala²,D-Leu⁵]enkephalin (DADL); D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH₂ (SEQ ID NO:1) (CTOP); [D-Ala²,N-MePhe⁴,Met(O)⁵-

ol]enkephalin (FK-33824); Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH₂ (SEQ ID NO: 2) ([D-Ala²]deltorphan I; Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH₂ (SEQ ID NO:3) ([D-Ala²,Glu⁴]deltorphan II; Tyr-Pro-Phe-Pro-NH₂ (SEQ ID NO:4) (morphiceptin); Tyr-Pro-MePhe-D-Pro-NH₂ (SEQ ID NO:5) (PL-017); and [D-Ala²,Leu⁵,Cys⁶]enkephalin; (5) leukotriene antagonists preferably independently selected from ablukast; ablukast sodium; cinalukast; iralukast; montelukast sodium; ontazolast; pobilukast edamine; pranlukast; ritolukast; sulukast; tomelukast; verlukast; and zafirlukast; (6) leukotriene biosynthesis (5-lipoxygenase) inhibitors preferably independently selected from docebenone; enazadrem phosphate; and zileuton; (7) thromboxane receptor antagonists preferably independently selected from seratrodastr; (8) anticholinergic agents preferably independently selected from ipratropium bromide; (9) autocoids including bradykinin and kallidin, and their analogous derivatives having agonist and antagonist activity useful for the treatment of pain and chronic inflammatory conditions, preferably independently selected from Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (SEQ ID NO:6) (bradykinin); Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (SEQ ID NO: 7) (kallidin); Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe (des-Arg⁹-bradykinin) (SEQ ID NO:8); Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe (des-Arg¹⁰-kallidin) (SEQ ID NO:9); Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu (des-Arg⁹-[Leu⁸]-bradykinin) (SEQ ID NO:10); Arg-Pro-Pro-Gly-Phe-Ser-[D-Phe]-Phe-Arg ([D-Phe⁷]-bradykinin) (SEQ ID NO:11); and [D-Arg]-Arg-Pro-Hyp-Gly-Thi-Ser-Tic-Oic-Arg (SEQ ID NO: 12) (HOE 140), where Hyp is *trans*-4-hydroxy-Pro; Thi is β-(2-thienyl)-Ala; Tic is [D]-1,2,3,4-tetrahydroquinolin-3-yl-carbonyl; and Oic is (3as,7as)-octahydroindol-2-yl-carbonyl; and (10) cytokines consisting of colony-stimulating factors and interleukins preferably independently selected from granulocyte colony-

stimulating factor (G-CSF); granulocyte macrophage colony-stimulating factor (GM-CSF); and interleukin-1 (IL-1) through interleukin-12 (IL-12).

Add, after Page 76, line 7, the Sequence Listing, a paper copy of which is attached hereinafter.